Spironolactone Discontinuation Before Pregnancy: Critical Considerations

Introduction to Spironolactone Discontinuation

The American Academy of Dermatology recommends that all women of childbearing age taking spironolactone must receive counseling about pregnancy avoidance and use reliable contraception 1
The critical period for antiandrogenic effects of spironolactone appears to be the first 6-8 weeks of pregnancy when male sexual differentiation occurs, highlighting the importance of pre-conception planning 2

For heart failure during pregnancy, spironolactone and other mineralocorticoid receptor antagonists should be avoided due to antiandrogenic effects in the first trimester, and alternatives like hydralazine and long-acting nitrates can be used 3
The American Heart Association implies that beta-1 selective beta-blockers are preferred for managing heart failure in pregnancy, avoiding the first trimester if possible 3

The American College of Cardiology suggests that in women with severe heart failure where spironolactone discontinuation poses significant maternal risk, pregnancy should be carefully planned with cardiology consultation, and alternative agents should be maximized 4
The American Academy of Dermatology advises that no hormonal therapy for hirsutism should be used during pregnancy, and focus should be on mechanical hair removal methods 1

For disease management during the washout period, the American Academy of Dermatology recommends transitioning to topical therapies or considering oral antibiotics for acne, and substituting with pregnancy-safe antihypertensives like methyldopa or labetalol for hypertension 1
The American Heart Association implies that for heart failure, other guideline-directed medical therapies that are pregnancy-compatible should be optimized 3

De 6 casos reportados de exposición a espironolactona durante el embarazo, 5 resultaron en desarrollo genital masculino normal y 1 caso presentó genitales ambiguos en un recién nacido cuya madre recibió espironolactona hasta la semana 5 de gestación, según la Academia Americana de Dermatología 5, 6

La FDA clasifica a la espironolactona como Categoría C, y establece que debe evitarse en mujeres embarazadas o advertir a la mujer embarazada del riesgo potencial para el feto masculino, según la FDA 7, 8, 9
La Sociedad Europea de Cardiología recomienda evitar los antagonistas de aldosterona durante el embarazo debido a su potencial para causar efectos antiandrogénicos en el primer trimestre 10

La Sociedad Europea de Cardiología sugiere que hidralazina y nitratos de acción prolongada pueden usarse en lugar de IECA/ARA-II durante el embarazo, y que betabloqueadores beta-1 selectivos son preferidos, evitando el primer trimestre si es posible 10, 11, 12
La FDA advierte que atenolol debe evitarse debido a restricción del crecimiento intrauterino, y que diuréticos deben usarse con precaución ya que pueden disminuir el flujo sanguíneo placentario 10, 13

La Academia Americana de Dermatología recomienda que las pacientes en edad fértil que toman espironolactona deben recibir consejería sobre evitar el embarazo, y que el uso concomitante de anticonceptivos orales combinados o dispositivo intrauterino hormonal se recomienda frecuentemente 7, 8, 9
La Sociedad Europea de Cardiología sugiere que algunos IECA han sido suficientemente probados en mujeres lactantes y son seguros, y que se requiere monitoreo del peso del niño durante las primeras 4 semanas como indicador de disfunción renal 10

The European Society of Cardiology recommends that aldosterone antagonists, such as spironolactone, should be avoided during pregnancy due to antiandrogenic effects in the first trimester 14, 15
Hydralazine and long-acting nitrates can be used as first-line alternatives for afterload reduction in heart failure during pregnancy 14, 15
Beta-1 selective beta-blockers, such as metoprolol, are indicated for all heart failure patients if tolerated, while atenolol should be avoided 14, 15
Furosemide and hydrochlorothiazide are the most frequently used diuretics when pulmonary congestion is present, but should only be used when necessary as they may decrease placental blood flow 14, 15
Dopamine and levosimendan can be used if inotropic drugs are required 14, 15
Newer-generation mineralocorticoid receptor antagonists, like eplerenone, have higher selectivity for the mineralocorticoid receptor with reduced antiandrogenic effects, but data for use during pregnancy remains lacking 14